Skip to main content
. Author manuscript; available in PMC: 2020 Dec 22.
Published in final edited form as: Mol Pharm. 2015 Oct 2;12(11):3986–3998. doi: 10.1021/acs.molpharmaceut.5b00432

Figure 8.

Figure 8.

(A) Tumor growth inhibition in Her2 positive SKOV3 xenograft mice treated twice (days 62 and 69) at 3 mg/kg. (B) Tumor growth inhibition in CD98 positive H446 (lung carcinoma) xenograft mice treated twice (days 41 and 48) at 3 mg/kg. (C) SKOV3 xenograft tumor model in NOG mice (insensitive to treatment with trastuzumab) treated once at 3 mg/kg with homogeneous (DBM) ADC 5 or with conventional (MC) ADC 3.